Seres Therapeutics announces interim results from SER-109 phase 2 ECOSPOR study
Seres Therapeutics announced interim 8-week results from the ongoing SER-109 Phase 2 ECOSPORTM clinical study for prevention of multiply recurrent Clostridium difficile infection. The study’s primary endpoint of reducing the relative risk of CDI recurrence at up to 8-weeks was not achieved. July 29, 2016